Research | Judith Tam ALK Lung Cancer Research Initiative

At the heart of the Judith Tam ALK Lung Cancer Research Initiative is a passion for discovery and a commitment to making a meaningful impact on the lives of people affected by ALK+ lung cancer. Our research portfolio spans basic science, translational studies, and clinical innovation—each project designed to answer pressing questions, develop better therapies, and improve outcomes. Explore our active, developing, and past research projects below. Each project listing links to more detailed information, including project aims, leadership, publications, and recent news.

Our collaborators

Advancing meaningful research is a team effort, and we are deeply grateful to our valued collaborators whose expertise and partnership accelerate progress in ALK+ lung cancer research. Together, we are pushing boundaries, sharing knowledge, and making a greater impact for patients and families.

We extend special thanks to our notable collaborators:

GenPrex

Advancing novel gene therapies and translational approaches for lung cancer treatment.

Genprex is honored to have an active and productive collaboration with the Judith Tam ALK Lung Cancer Research Initiative.  Through this partnership, our company has been able to conduct important and successful preclinical research that opens the door for a new clinical trial that of quaratusugene ozeplasmid (REQORSA) and seeks to offer additional treatment options for patients with ALK rearrangements.” 

– Dr. Mark Berger, MD, Chief Medical Officer for Genprex

Seoul National University

Providing cutting-edge clinical insights, international collaboration, and vital tissue samples—directly supporting our work in modeling and characterizing early ALK-dependent tumorigenesis.

ALK Positive Summit

Empowering the patient community and accelerating research through advocacy, engagement, and support.

We thank each of our collaborators for their dedication and partnership. Together, we are making a real difference in the fight against ALK+ lung cancer.